(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 2 June 2005 (02.06.2005)

PCT

(10) International Publication Number WO 2005/048999 A2

(51) International Patent Classification⁷:

A61K 31/00

(21) International Application Number:

PCT/EP2004/013070

(22) International Filing Date:

17 November 2004 (17.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0326967.7 19 November 2003 (19.11.2003) GB 0327937.9 2 December 2003 (02.12.2003) GB 0401862.8 28 January 2004 (28.01.2004) GB

- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HAGAN, James, Joseph [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM17 5AW (GB). RATTI, Emiliangelo [IT/IT]; GlaxoSmithKline, via Alessandro Fleming 2, I-37135 Verona (IT). ROUTLEDGE, Carol [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM17 5AW (GB).

- (74) Agent: GIDDINGS, Peter, John; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS

$$R^3O_2S$$
 R^2 (I)

$$Q^{10} \qquad \qquad Q^{5} \qquad \qquad \text{(III)}$$

$$Q^{4}O_{2}S \qquad \qquad Y \qquad$$

(57) Abstract: The invention concerns the use of compounds of formula (I), (II) and (III): which are COX-2 (cyclooxygenase-2) inhibitors, and pharmaceutically acceptable salts or solvates thereof, for the treatment of depressive disorders in combination with an effective amount of a second component which is a selective serotonin reuptake inhibitor.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.